STRATEC Biomedical AG / Key word(s): Miscellaneous
05.06.2013 15:47

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

STRATEC's Birkenfeld site suffers water damage

Birkenfeld, June 5, 2013

STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) reported today that the heavy rains that fell in the past few days have caused surface water to damage several buildings at STRATEC's complex in Birkenfeld, Germany.

Although the clean-up process has now been largely completed, business operations at the Birkenfeld site are likely to be affected for a period of several weeks. Particularly, some delays in services such as project deliverables are to be expected.

The aforementioned service delays will primarily affect the 'Prototyping' and 'Reliability Testing' divisions, leading to postponed recognition of revenue that could be as high as EUR 3 million. The impact on revenue and earnings will mainly be felt the in the second quarter of 2013. Due to the current uncertainties, the publication of the financial guidance for 2013 and subsequent years, which was slated for June 2013, will now coincide with the publication of the half-yearly results for 2013 scheduled to take place on July 23, 2013.

An insurance claim will be made for the full extent of material and business interruption damages.

---

Information and Explaination of the Issuer to this News:
About STRATEC

STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information can be obtained from:

STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com

05.06.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

 
Language:     English
Company:      STRATEC Biomedical AG
              Gewerbestr. 37
              75217 Birkenfeld
              Germany
Phone:        +49 (0)7082 7916 0
Fax:          +49 (0)7082 7916 999
E-mail:       info@stratec.com
Internet:     www.stratec.com
ISIN:         DE0007289001
WKN:          728900
Indices:      TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart  
End of Announcement DGAP News-Service  

---